ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1150

Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis

Arianna De Matteis1, Denise Pires Marafon1, Ivan Caiello1, Manuela Pardeo1, Giulia Marucci1, Emanuela Sacco1, Giusi Prencipe1, Fabrizio De Benedetti2 and Claudia Bracaglia1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 2Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy

Meeting: ACR Convergence 2020

Keywords: Biomarkers, chemokines, interferon, Juvenile idiopathic arthritis, macrophage activation syndrome

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 8, 2020

Session Title: Pediatric Rheumatology – Clinical Poster II: Systemic JIA, Autoinflammatory, & Scleroderma

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Macrophage Activation Syndrome (MAS) and secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm, in which IFNγ plays a pivotal role. In this study we aimed to evaluate clinical characteristics of sHLH, MAS and systemic Juvenile Idiopathic Arthritis (sJIA) patients at disease onset. We compared laboratory parameters of hyperinflammation (platelet count, ferritin, AST, triglycerides, fibrinogen) and IFNγ related biomarkers in samples collected in three different time points: active disease (T0), 7-10 days from starting therapy (T1) and in clinical inactive disease (from 1 to 3 months from onset) (T2).

Methods: Routine laboratory parameters of disease activity and severity were collected from a cohort of 82 patients with sHLH (38), MAS in the context of sJIA (26), and sJIA (18) at T0, T1 and T2. Serum levels of the IFNγ related biomarkers (CXCL9, CXCL10, neopterin and IL-18) were measured at each time points by ELISA.

Results: A total of 306 samples were collected. Fever was present in the majority of patients (95%), while splenomegaly was more frequently in MAS (65%) and sHLH (63%) compared to sJIA (17%). Laboratory characteristics at T0 are detailed in Table 1. Using the 2016 classification criteria for MAS [1], we found that platelet count is a specific parameter, any patient with sJIA had a value < 181x109/liter; while ferritin is a sensitive one, 94% of patients with MAS had ferritin > 684 mg/ml. CXCL9, CXCL10 and neopterin levels in T0 were significantly higher in MAS and in sHLH compared to sJIA, while IL-18 was significantly higher only in MAS group (Table 2). The ROC curves performed for each biomarker in MAS showed a statistically significant AUCs (p< 0.05). In sHLH the AUCs was significant for CXCL9, CXCL10 and Neopterin (p< 0.0001), while for IL-18 was not (p= 0.9) (Figure 1). In MAS CXCL9 and neopterin were significantly correlated to laboratory parameters of hyperinflammation as well as IL-18, except for ferritin. In sHLH only neopterin was significantly correlated to platelet count and triglycerides. CXCL9, CXCL10, neopterin and IL-18 levels progressively lowered at T1 and normalized in T2. CXCL9 decreased faster compared to neopterin, with a similar trend of laboratory parameters.

Conclusion: Our results confirme that platelet counts and ferritin have and high specificity and sensitivity, respectively, to diagnose MAS in the context of sJIA. Moreover, our results confirmed that IFNγ related biomarkers are significantly high in patients with MAS and sHLH and could be useful for diagnosis in addition to traditional laboratory parameters. CXCL9 seems to be more related to active disease, while neopterin seems to be more useful to follow the disease course. As already known, IL-18 is a specific biomarker for MAS. 

Reference.

1. Ravelli A et al. Ann Rheum Dis. 2016 Mar;75(3):481-9.


Disclosure: A. De Matteis, None; D. Pires Marafon, None; I. Caiello, None; M. Pardeo, None; G. Marucci, None; E. Sacco, None; G. Prencipe, None; F. De Benedetti, Novartis, 2, 8, Novimmune, 2, 9, Sobi, 2, 8, 9, Roche, 2, 8, Pfizer, 2, Sanofi, 2, AbbVie, 8; C. Bracaglia, SOBI, 8.

To cite this abstract in AMA style:

De Matteis A, Pires Marafon D, Caiello I, Pardeo M, Marucci G, Sacco E, Prencipe G, De Benedetti F, Bracaglia C. Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/traditional-laboratory-parameters-and-new-biomarkers-in-macrophage-activation-syndrome-and-secondary-hemophagocytic-lymphohistiocytosis-2/. Accessed February 25, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/traditional-laboratory-parameters-and-new-biomarkers-in-macrophage-activation-syndrome-and-secondary-hemophagocytic-lymphohistiocytosis-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.